Multiple reports have linked high POLR3G (RPC7α) expression with unfavorable outcomes across distinct cancer subtypes [14,15,16,17]; however, few studies have directly compared clinical signatures associated with POLR3G, POLR3GL, or other Pol III subunits. This evidence concerns the gene POLR3GL and cancer.